Contraindicated (1)bortezomib will raise the stage or effect of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors could raise mavacamten systemic exposure, resulting in heart failure on account of systolic dysfunction. Unlock 38% additional drug discovery time and do away with determination-earning uncertainties with this https://mepyramine44321.blogrelation.com/32710853/the-smart-trick-of-atpenin-a5-that-no-one-is-discussing